Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical trials of neuroprotection for Parkinson's disease.

× No keyword cloud information.

10 in total

Review 1. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors: Anthony H V Schapira
Journal: CNS Drugs Date: 2011-12-01 Impact factor: 5.749

Review 2. Issues for clinical drug development in neurodegenerative diseases.

Authors: Michel Dib
Journal: Drugs Date: 2005 Impact factor: 9.546

3. Behavioral effects of cocaine mediated by nitric oxide-GAPDH transcriptional signaling.

Authors: Risheng Xu; Anthony V Serritella; Tanusree Sen; Justin M Farook; Thomas W Sedlak; Jay Baraban; Solomon H Snyder; Nilkantha Sen
Journal: Neuron Date: 2013-05-22 Impact factor: 17.173

Review 4. Riluzole in the treatment of mood and anxiety disorders.

Authors: Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal: CNS Drugs Date: 2008 Impact factor: 5.749

5. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Authors: Orly Weinreb; Tamar Amit; Yotam Sagi; Noam Drigues; Moussa B H Youdim
Journal: J Neural Transm (Vienna) Date: 2009-04-25 Impact factor: 3.575

6. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.

Authors: P Bonsi; D Cuomo; G Martella; G Sciamanna; M Tolu; P Calabresi; G Bernardi; A Pisani
Journal: Curr Neuropharmacol Date: 2006-01 Impact factor: 7.363

7. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.

Authors: Lin W Hung; Victor L Villemagne; Lesley Cheng; Nicki A Sherratt; Scott Ayton; Anthony R White; Peter J Crouch; SinChun Lim; Su Ling Leong; Simon Wilkins; Jessica George; Blaine R Roberts; Chi L L Pham; Xiang Liu; Francis C K Chiu; David M Shackleford; Andrew K Powell; Colin L Masters; Ashley I Bush; Graeme O'Keefe; Janetta G Culvenor; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Andrew F Hill; David I Finkelstein; Kevin J Barnham
Journal: J Exp Med Date: 2012-04-02 Impact factor: 14.307

8. The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.

Authors: Jia-Jie Mo; Lin-Ying Liu; Wei-Bin Peng; Jie Rao; Zhou Liu; Li-Li Cui
Journal: BMC Neurol Date: 2017-06-02 Impact factor: 2.474

9. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.

Authors: Nicolas Kerckhove; Jérome Busserolles; Trevor Stanbury; Bruno Pereira; Valérie Plence; Franck Bonnetain; Ivan Krakowski; Alain Eschalier; Denis Pezet; David Balayssac
Journal: BMJ Open Date: 2019-06-09 Impact factor: 2.692

Review 10. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.

Authors: Timothy S Kern
Journal: Exp Diabetes Res Date: 2007

10 in total